손발톱 진균증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Onychomycosis Treatment Market size is expected to reach USD 12.51 Billion in 2034 from USD 5.78 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The onychomycosis treatment market is poised for significant growth, driven by the increasing prevalence of fungal nail infections and the rising awareness of available treatment options. Onychomycosis, characterized by the infection of the nail bed and surrounding tissues, affects a substantial portion of the population, leading to discomfort and aesthetic concerns. As healthcare providers and patients alike recognize the importance of effective treatment, the demand for innovative therapies is expected to rise. This market is witnessing a shift towards more effective and patient-friendly treatment modalities, including topical antifungals, oral medications, and laser therapies.

In addition to traditional treatment options, the onychomycosis treatment market is benefiting from advancements in drug formulation and delivery systems. Novel formulations that enhance the penetration of antifungal agents into the nail matrix are gaining traction, improving treatment efficacy and reducing the duration of therapy. Furthermore, the development of combination therapies that target multiple aspects of the infection is emerging as a promising approach, offering patients a more comprehensive solution. As research continues to unveil new therapeutic targets and mechanisms of action, the onychomycosis treatment market is expected to expand, providing patients with a wider array of effective treatment options.

Moreover, the increasing focus on preventive care and patient education is shaping the onychomycosis treatment landscape. Healthcare providers are emphasizing the importance of early diagnosis and intervention, as well as educating patients about proper foot hygiene and nail care practices. This proactive approach is likely to drive demand for treatment options, as patients become more informed about the risks associated with untreated fungal infections. As the onychomycosis treatment market continues to evolve, the combination of innovative therapies, enhanced patient education, and a growing emphasis on prevention will play a crucial role in addressing the challenges posed by this common condition.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Drugs
• Lasers
• Photodynamic Therapy

By Disease Indication

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

By Age Group

• 0 to 18 Years
• 18 to 39 Years
• 40 to 64 Years
• 65 Years & Above

By Gender

• Male
• Female

By Distribution Channel

• Institutional Sales
• Retail Sales

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, Sanofi SA, Medimetriks Pharmaceuticals Inc, Galderma, Johnson Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health Inc, Pfizer Inc, Almirall SA, Bayer AG, Viatris Inc, GlaxoSmithKline plc, Cipla Ltd, Dr Reddys Laboratories Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lasers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Photodynamic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Distal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. White Superficial Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Proximal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Candidal Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Total Dystrophic Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age Group
• 6.2. 0 to 18 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. 18 to 39 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. 40 to 64 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. 65 Years & Above Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Gender
• 7.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Disease Indication
  • 9.2.3 By Age Group
  • 9.2.4 By Gender
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Disease Indication
  • 9.3.3 By Age Group
  • 9.3.4 By Gender
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Disease Indication
  • 9.4.3 By Age Group
  • 9.4.4 By Gender
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Disease Indication
  • 9.5.3 By Age Group
  • 9.5.4 By Gender
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Disease Indication
  • 9.6.3 By Age Group
  • 9.6.4 By Gender
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONYCHOMYCOSIS TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Teva Pharmaceutical Industries Ltd
  • 11.2.2 Sanofi S.A
  • 11.2.3 Medimetriks Pharmaceuticals Inc
  • 11.2.4 Galderma
  • 11.2.5 Johnson & Johnson
  • 11.2.6 Novartis AG
  • 11.2.7 Moberg Pharma AB
  • 11.2.8 Cardinal Health Inc
  • 11.2.9 Pfizer Inc
  • 11.2.10 Almirall S.A
  • 11.2.11 Bayer AG
  • 11.2.12 Viatris Inc
  • 11.2.13 GlaxoSmithKline Plc
  • 11.2.14 Cipla Ltd
  • 11.2.15 Dr. Reddy'S Laboratories Ltd